Board of Directors
Total Page:16
File Type:pdf, Size:1020Kb
Annual Review 2013 Board of Directors Dennis A. Ausiello, M.D. W. Don Cornwell Frances D. Fergusson, Ph.D Director, Center for Founder and Retired President Emeritus Assessment Technology and Chairman and CEO Vasser College Continuous Health (CATCH). Granite Broadcasting (2,4,5) Physician-in-Chief, Corporation Emeritus at Massachusetts (1,2,4,5) General Hospital (1,3,4,5) Helen H. Hobbs, M.D. Constance J. Horner James M. Kilts Investigator Former Assistant to Founding Partner Howard Hughes the President of the Centerview Capital Medical Institute United States and Director (2,5) (3,4,5) of Presidential Personnel (3,4,5) George A. Lorch Shantanu Narayen Suzanne Nora Johnson Chairman Emeritus President and Chief Executive Retired Vice Chairman Armstrong Holdings, Inc. Offi cer and Director of The Goldman Sachs (6) Adobe Systems Inc. Group, Inc. (3,5) (1,2,5) Ian C. Read Stephen W. Sanger Marc Tessier-Lavigne, Ph.D. Chairman and CEO Retired Chairman and CEO President General Mills Rockefeller University (1,3,5) (4,5) (1) Audit Committee (2) Compensation Committee (3) Corporate Governance Committee (4) Regulatory and Compliance Committee (5) Science and Technology Committee (6) Lead Independent Director Pfi zer Annual Review 2013 www.pfi zer.com/annual Our Business > Board of Directors 1 Annual Review 2013 Executive Leadership Team Ian C. Read Albert Bourla Frank A. D’Amelio Chairman and CEO Group President, Executive Vice President, Global Vaccines, Business Operations and Oncology and Consumer Chief Financial Offi cer Healthcare Business Mikael Dolsten, M.D. Ph.D. Geno Germano Chuck Hill President, Group President, Executive Vice President, Worldwide Research Global Innovative Worldwide and Development Pharma Business Human Resources Rady Johnson Doug Lankler Freda C. Executive Vice President, Executive Vice President, Lewis-Hall, M.D. Chief Compliance General Counsel Executive Vice President and Risk Offi cer and Chief Medical Offi cer Anthony J. Maddaluna Laurie Olson Sally Susman Executive Vice President Executive Vice President, Executive Vice President, and President, Strategy, Portfolio and Corporate Affairs Pfi zer Global Supply Commercial Operations John Young Group President, Global Established Pharma Business Pfi zer Annual Review 2013 www.pfi zer.com/annual Our Business > Executive Leadership Team 2 Annual Review 2013 How We Are Organized Our new operating structure represents the next steps in Pfi zer’s journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to deliver value to patients and our shareholders. Through this evolution, we are enabling greater independence, focus and responsiveness for our commercial businesses. Global Commercial Business Global Innovative Pharma Business Global Global Established Vaccines, Oncology Pharma and Consumer Business Healthcare Business Worldwide Pfi zer Enabling Research & Global Supply Functions Development Pfi zer Annual Review 2013 www.pfi zer.com/annual Our Business > How We Are Organized 3 Annual Review 2013 Global Innovative Pharma Business Global Innovative Pharma (GIP) is focused • Growing global business with potential in • A robust pipeline of medicines in on development, registration and developed and targeted emerging markets inflammation, cardiovascular metabolic, commercialization of novel, value creating • Launch brands include Xeljanz, Eliquis pain and rare diseases medicines that significantly improve and Duavee • Transformative capabilities that will help patients’ lives. GIP includes: • Market-leading strategic brands include to meet the challenges of an evolving Enbrel, Lyrica (U.S., Japan), Viagra (U.S.) global health care market and Champix Global Established Pharma Business Global Established Pharma (GEP) is a • Products that will go off patent (also • Legacy emerging markets large, attractive, highly diverse known as Peri-LOE) business in developed • Growth opportunities which include and profitable business with unique markets, including major brands such as Biosimilars and sterile injectables, opportunities across portfolios and Celebrex and Zyvox partnerships in key markets, and geographies. GEP is comprised of four • Legacy established products, comprised targeted opportunities in the distinct portfolio segments: of mature off-patent medicines in developed markets developed markets Global Vaccines, Oncology and Consumer Healthcare Business Global Vaccines, Oncology and Consumer • Each of these businesses is poised for Healthcare (VOC) is comprised of three high, organic growth over time separate, unique businesses that share • Each business requires distinct certain key elements: specializations and operating models in science, talent and market approach • Structure provides each business with the dedicated resources required to further strengthen and position it to be a market leader on a global basis Pfizer Annual Review 2013 www.pfizer.com/annual Our Business > How We Are Organized 4 Annual Review 2013 RESPONSIBLE BUSINESS Governance and Ethics At Pfizer, we understand that good corporate governance is essential to our standing as a trusted member of society, and we conduct ourselves accordingly. Board of Directors Compliance Pfizer’s Board of Directors is responsible for the oversight We believe that compliance with all applicable laws is of management, including the overall strategic direction of integral to our ability to serve society. We train colleagues the company, and for the company’s policies on governance, extensively in compliance and have an organizational structure executive compensation and compliance. designed to ensure good oversight of our colleagues, vendors and business partners. Read more about our Board of Directors here. Read more about our Compliance here. Ethical Sales and Marketing Disclosing Payment to We are committed to promoting our products responsibly, educating patients and providers about their appropriate use, Health Care Professionals and reporting about our business practices in a fashion that We do not pay health care professionals for prescribing our promotes transparency. medicines or as an inducement for promoting our products. We believe it is appropriate and ethical to fairly compensate Read more about our Ethical Sales and Marketing here. health care professionals for work they do on our behalf. Read more about our Disclosing Payment to Health Care Direct-to-Consumer Professionals here. Advertising in the U.S. Our strict internal standards, going beyond compliance with Human Rights the law, have been developed to ensure that the information we share with patients is scientifically sound, balanced, easy to Pfizer strives to uphold human rights in all our business activities. understand and helpful in encouraging them to consult with a We also work to advance human rights by working to improve the health care professional. health of people around the world. Read more about our Direct-to-Consumer Advertising here. Read more about our Human Rights here. Pfizer Annual Review 2013 www.pfizer.com/annual Our Business > Responsible Business > Governance and Ethics 5 Annual Review 2013 RESPONSIBLE BUSINESS Environment Committed to a Sustainable Future Our commitment to advancing health includes being good stewards of the environment. We constantly assess our business practices and advance those that we believe produce measurable value for society Our Path to a Sustainable Future — and our business, while minimizing risk to our shareholders. Our strategic approach focuses on reducing energy and water 2020 Public Goals* consumption in addition to innovative ways to manage waste. Our “green journey” focuses on three areas key to our business: ENERGY — mitigating climate change and its impacts 2 0% 15% WASTE — minimizing the environmental impact of our GHG Emissions Waste Disposed products and processes WATER — managing water resources sustainably For a comprehensive view of our contributions to a sustainable future, see here. Also, by the end of 2015, Pfizer plans to announce targets 5% that it believes have the potential to result in meaningful Water Use environmental improvement across our supply chain by the end of 2020. *Compared with Pfizer’s 2012 baseline. Pfizer Annual Review 2013 www.pfizer.com/annual Our Business > Responsible Business > Environment 6 Annual Review 2013 RESPONSIBLE BUSINESS Building on a Strong Record Carbon Disclosure Project We have a strong record in reducing Recognizes Pfizer’s greenhouse gas (GHG) emissions. From Sustainability Efforts 2000 to 2007, we reduced our GHG In its 2013 rating, Carbon Disclosure emissions by 20 percent. From 2007 to Project (CDP) scored Pfizer 91 out of 2012, we reduced them an additional 100 for Climate Disclosure. Pfizer has 25 percent. Our current goal is to reduce participated in the CDP rankings since our GHG emissions by another 20 percent their inception, and this year’s rating by 2020, from our 2012 baseline, which — our highest — places us among the is consistent with the 60 to 80 percent top group of health care companies reduction by 2050 that scientists in both the S&P 500 and the Financial indicate is necessary to stabilize Times Global 500 listings. In 2012, Pfizer global temperatures. was also commended for incorporating sustainability information in commercial Pfizer is also an acknowledged leader tender requests, and for implementing in Green Chemistry, having made 116 energy efficiency projects yielding significant solvent and waste reductions,